Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: Can biomarkers predict response?
Endometrial Cancer
Endometrial Hyperplasia
Levonorgestrel intrauterine system
Mirena® Biomarker
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
28
10
2020
revised:
11
02
2021
accepted:
13
02
2021
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
epublish
Résumé
Endometrial Cancer (EC) is the most common gynaecologic malignancy in the developed world, and is increasing in premenopausal women. The surgical standard of care for early-stage EC is not possible in women with concurrent comorbidities or women who desire a fertility sparing approach. The Levonorgestrel Intrauterine System (LNG-IUS) is gaining traction as an alternative treatment for endometrial hyperplasia and early stage EC in inoperable women. Whilst early evidence appears promising, predictive biomarkers need to be established to determine non-responders, which make up one in three women. This timely review discusses the current literature around the identification of clinical, molecular and novel biomarkers that show potential to predict response to progesterone treatment, including the LNG-IUS.
Identifiants
pubmed: 33718563
doi: 10.1016/j.gore.2021.100732
pii: S2352-5789(21)00037-0
pmc: PMC7933258
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100732Informations de copyright
© 2021 The Authors.
Références
Acta Obstet Gynecol Scand. 2019 Sep;98(9):1086-1099
pubmed: 30793281
Cell Tissue Res. 2005 Oct;322(1):53-61
pubmed: 15947972
Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1531-43
pubmed: 12496040
Radiother Oncol. 2016 Jan;118(1):167-72
pubmed: 26743834
Eur J Obstet Gynecol Reprod Biol. 2008 Aug;139(2):169-75
pubmed: 18440693
Hum Reprod. 2013 Nov;28(11):2966-71
pubmed: 23975691
Maturitas. 2007 Jun 20;57(2):210-3
pubmed: 17270370
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Obstet Gynecol. 2001 May;97(5 Pt 1):707-11
pubmed: 11339920
Cancer. 2017 Mar 1;123(5):802-813
pubmed: 28061006
Ther Clin Risk Manag. 2009 Jun;5(3):561-74
pubmed: 19707273
Endocr Relat Cancer. 2004 Sep;11(3):523-35
pubmed: 15369452
Cancer Res. 2013 Aug 1;73(15):4697-710
pubmed: 23744837
Fertil Steril. 2011 Jan;95(1):420-2
pubmed: 20723889
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Minim Invasive Gynecol. 2016 Jan;23(1):53-61
pubmed: 26282516
J Minim Invasive Gynecol. 2014 Mar-Apr;21(2):259-65
pubmed: 24012923
Am J Obstet Gynecol. 2021 Feb;224(2):191.e1-191.e15
pubmed: 32805208
BJOG. 2014 Mar;121(4):477-86
pubmed: 24286192
Crit Rev Oncol Hematol. 2011 Sep;79(3):278-92
pubmed: 20833559
Crit Rev Oncol Hematol. 2006 Jun;58(3):242-56
pubmed: 16436330
Gynecol Oncol. 2005 Jun;97(3):740-50
pubmed: 15885761
Gynecol Oncol Rep. 2018 Sep 12;26:45-48
pubmed: 30255125
J Transl Med. 2019 Feb 27;17(1):58
pubmed: 30813939
Mod Pathol. 2000 Mar;13(3):309-27
pubmed: 10757341
J Gynecol Oncol. 2016 Jan;27(1):e8
pubmed: 26463434
ScientificWorldJournal. 2014 Jan 12;2014:709736
pubmed: 24526917
Int J Gynecol Cancer. 2004 Mar-Apr;14(2):348-53
pubmed: 15086736
Cancer. 1985 Jul 15;56(2):403-12
pubmed: 4005805
Clin Cancer Res. 2013 Mar 1;19(5):1094-105
pubmed: 23319822
Discov Med. 2012 Sep;14(76):215-22
pubmed: 23021376
Menopause. 2005 Nov-Dec;12(6):668-78
pubmed: 16278609
Arch Gynecol Obstet. 2019 Mar;299(3):801-808
pubmed: 30706187
Gynecol Oncol. 2006 May;101(2):214-23
pubmed: 16325240
Gynecol Oncol. 2017 Jul;146(1):34-38
pubmed: 28427775
Am J Obstet Gynecol. 2010 Dec;203(6):547.e1-10
pubmed: 20934679
Am J Obstet Gynecol. 2015 Oct;213(4):469-78
pubmed: 25797236
Cancer Causes Control. 2019 Feb;30(2):121-127
pubmed: 30671687
Gynecol Oncol. 2015 Dec;139(3):419-23
pubmed: 26494424
Onco Targets Ther. 2017 Jun 06;10:2865-2871
pubmed: 28652768
BJOG. 2017 Sep;124(10):1576-1583
pubmed: 28128512
Best Pract Res Clin Obstet Gynaecol. 2012 Apr;26(2):257-66
pubmed: 22078749
Prz Menopauzalny. 2017 Sep;16(3):107-111
pubmed: 29507578
Pathol Res Pract. 1992 Oct;188(7):856-9
pubmed: 1448376
Gynecol Oncol. 2013 Jul;130(1):58-63
pubmed: 23603367
BJOG. 2020 Jul;127(8):1000
pubmed: 32350997
Anticancer Res. 2017 May;37(5):2529-2536
pubmed: 28476823
Cancers (Basel). 2020 Jan 23;12(2):
pubmed: 31979212
J Womens Health (Larchmt). 2017 Apr;26(4):368-373
pubmed: 27901412
Am J Obstet Gynecol. 2012 Jul;207(1):36.e1-8
pubmed: 22727345
Eur J Obstet Gynecol Reprod Biol. 2018 Dec;231:104-110
pubmed: 30342311
Am J Obstet Gynecol. 2020 Oct 9;:
pubmed: 33039397
Cancer Sci. 2011 Mar;102(3):557-64
pubmed: 21205080
Gynecol Oncol. 2016 Jan;140(1):152-60
pubmed: 26524723
Am J Epidemiol. 1989 Jun;129(6):1120-31
pubmed: 2729251
Oncol Res. 2019 Sep 23;27(9):1051-1060
pubmed: 31072420
J Gynecol Oncol. 2019 Jul;30(4):e57
pubmed: 31074240
Int J Gynecol Cancer. 2015 Sep;25(7):1258-65
pubmed: 26186070
Onco Targets Ther. 2020 Nov 13;13:11669-11688
pubmed: 33235459
Oncogene. 2016 Sep 29;35(39):5191-201
pubmed: 26996671
Obstet Gynecol. 2018 Jan;131(1):109-116
pubmed: 29215513
Br J Cancer. 2016 Sep 6;115(6):725-30
pubmed: 27537387
Acta Obstet Gynecol Scand. 2010 Mar;89(3):393-8
pubmed: 20199355
Anticancer Res. 2018 May;38(5):2883-2889
pubmed: 29715112
Gynecol Oncol. 2014 Jan;132(1):33-7
pubmed: 24316307
Am J Obstet Gynecol. 2020 Jul;223(1):103.e1-103.e13
pubmed: 31978437
J Natl Compr Canc Netw. 2018 Feb;16(2):170-199
pubmed: 29439178
Cancer Chemother Pharmacol. 2019 Feb;83(2):277-287
pubmed: 30443761
Clin Endocrinol (Oxf). 2003 Jun;58(6):696-703
pubmed: 12780745